Fenwick Represents BioAge in $170M Series D Financing

Fenwick represented BioAge, a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, in its oversubscribed $170M Series D financing. The round was led by Sofinnova Investments with participation from Andreessen Horowitz (a16z) Bio + Health and new investors, including Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors and others.

BioAge will use the funds to support Phase 2 clinical development of their lead compound azelaprag, an oral apelin receptor agonist, in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity. More information can be obtained from the company’s announcement.

The transaction was led by corporate partner Matt Rossiter and included IP partners Jake Handy and Dan Becker and corporate associate Patrick White.